{"id":"NCT01765179","sponsor":"Clarus Therapeutics, Inc.","briefTitle":"Safety and Efficacy Trial of Testosterone Undecanoate","officialTitle":"Phase III, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU)in Hypogonadal Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2013-07","completion":"2013-07","firstPosted":"2013-01-10","resultsPosted":"2017-09-21","lastUpdate":"2017-12-12"},"enrollment":144,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Male Hypogonadism"],"interventions":[{"type":"DRUG","name":"Oral testosterone undecanoate","otherNames":[]}],"arms":[{"label":"Oral testosterone undecanoate","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to determine if oral testosterone undecanoate is effective and safe in the treatment of low testosterone in men.","primaryOutcome":{"measure":"Percentage of Treated Patients With an Average Serum Testosterone (T) Concentration (Cavg) Between 300 and 1000 ng/dL","timeFrame":"0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on day 114","effectByArm":[{"arm":"Oral Testosterone Undecanoate","deltaMin":87,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":16},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":144},"commonTop":["diarrhea","upper respiratory tract infection","dyspepsia","oedema peripheral","hypertension"]}}